AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
Sunshine Lake Pharma logo
Sunshine Lake PharmaPrivate
5 assets: 2 Ph 3, 3 Ph 1Clifutinib BesylatePhase 3 · Acute Myeloid Leukemia11 Apr 2027HECN30227 · Phase 1————
Suven Life Sciences logo
Suven Life SciencesSUVEN · NSE
2 assets: 1 Ph 3, 1 Ph 2MasupirdinePhase 3 · Alzheimer's DiseasePartial signalDec 2026Masupirdine · Phase 3———$33M
Suzhou Ribo Life Science logo
Suzhou Ribo Life Science6938 · HKEX
3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1QLC7401Phase 3 · Atherosclerotic Cardiovascular Disease7 Oct 2027QLC7401 · Phase 3———$39M
Suzhou Zelgen Biopharmaceuticals logo
Suzhou Zelgen Biopharmaceuticals688266 · SSE STAR Market
2 assets: 2 Ph 3jaktinibPhase 3 · Atopic DermatitisPartial signalFeb 2027jaktinib · Phase 1—$18MDec 2025—$60M
Swedish Orphan Biovitrum AB (publ) logo
Swedish Orphan Biovitrum AB (publ)SOBI · Nasdaq Stockholm
6 assets: 3 approved, 1 Ph 3, 1 Ph 2, 1 otherInotersenUS approval withdrawn · Transthyretin Amyloidosis with PolyneuropathyReliable signalMar 2027Olezarsen · Phase 3————
TaiMed Biologics logo
TaiMed Biologics4147 · TPEx
2 assets: 1 approved, 1 Ph 2TMB-365 / TMB-380Phase 2 · HIVMay 2027TMB-365 / TMB-380 · Phase 2————
Tasly Pharmaceutical Group logo
Tasly Pharmaceutical Group600535 · SSE
6 assets: 2 Ph 3, 4 Ph 2QiShenYiQiPhase 3 · Heart FailurePartial signal31 Dec 2026Jia Shen Tablet · Phase 2———$118M
Teijin logo
Teijin3401 · TSE
5 assets: 3 approved, 1 Ph 3, 1 Ph 2TrelagliptinPhase 3 · Type 2 DiabetesPartial signalAug 2027palopegteriparatide · Phase 3————
TG THERAPEUTICS, INC. logo
TG THERAPEUTICS, INC.TGTX · Nasdaq
2 assets: 1 approved, 1 Ph 1Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis1 Dec 2026Azercabtagene zapreleucel · Phase 1—$505MSep 2026Cash-flow positive$236M
Tiziana Life Sciences Ltd. logo
Tiziana Life Sciences Ltd.TLSA · Nasdaq
1 asset: 1 Ph 2ForalumabPhase 2 · Multiple Sclerosis1 Apr 2027Foralumab · Phase 2—$3.7MDec 2024~9.7 qtrs$5.2M
T
Tonghua Dongbao Pharmaceutical600867 · SSE
2 assets: 1 Ph 3, 1 Ph 2THDB0206Phase 3 · Type 2 DiabetesPartial signalNone on record—$205MDec 2025——
Transgene logo
TransgeneTNG · Euronext Paris
1 asset: 1 Ph 2T101Phase 2 · Chronic Hepatitis BNone on record————
TransThera Sciences (Nanjing), Inc. logo
TransThera Sciences (Nanjing), Inc.2617 · HKEX
1 asset: 1 Ph 3TinengotinibPhase 3 · CholangiocarcinomaWeak signalDec 2026Tinengotinib · Phase 3————
TScan Therapeutics, Inc. logo
TScan Therapeutics, Inc.TCRX · Nasdaq
2 assets: 1 Ph 3, 1 Ph 1TSC-101Phase 3 · Hematologic MalignanciesJun 2029TSC-101 · Phase 3—$78MSep 2026~2.8 qtrs$91M
TYK Medicines, Inc. logo
TYK Medicines, Inc.2410 · HKEX
1 asset: 1 Ph 3AsandeutertinibPhase 3 · Non-Small Cell Lung CancerWeak signal1 Dec 2027Asandeutertinib · Phase 2———$34M
UCB logo
UCBUCBJY · OTC
16 assets: 10 approved, 1 Ph 3, 3 Ph 2, 2 Ph 1Staccato AlprazolamPhase 3 · EpilepsyReliable signal21 Dec 2026bimekizumab · Phase 3—no price since 18 Aug 2026——~$1.9B
Upsher-Smith Laboratories, LLC logo
Upsher-Smith Laboratories, LLC6472 · TWSE
2 assets: 2 approvedApproved assets onlyNone on record————
Vaccinex, Inc. logo
Vaccinex, Inc.VCNX · OTC
1 asset: 1 Ph 2PepinemabPhase 1/2 · Alzheimer's DiseaseWeak signal31 Dec 2028Pepinemab · Phase 1/2—no price since 18 Aug 2026$1.1MDec 2024Ended Jan 2025$13M
Vaxxinity logo
VaxxinityVAXX · OTC
2 assets: 1 Ph 2, 1 Ph 1UB-311Phase 2 · Early Alzheimer's DiseaseNone on record—no price since 17 Aug 2026$31MDec 2023Ended Jul 2024$36M
Vigonvita Life Sciences logo
Vigonvita Life Sciences2630 · HKEX
2 assets: 2 Ph 2LV232Phase 2 · Major Depressive DisorderWeak signal1 Sep 2027LV232 · Phase 2————
VISEN Pharmaceuticals logo
VISEN Pharmaceuticals2561 · HKEX
2 assets: 2 approvedApproved assets onlyAug 2027palopegteriparatide · Phase 3————
Voronoi, Inc logo
Voronoi, Inc310210 · KOSDAQ
2 assets: 2 Ph 2EnozertinibPhase 1/2 · Non-Small Cell Lung CancerDec 2026Enozertinib · Phase 1————
Windtree Therapeutics logo
Windtree TherapeuticsWINT · OTC
1 asset: 1 Ph 2rostafuroxinPhase 2 · Resistant Hypertension with Adducin/Ouabain PolymorphismsNone on record—no price since 14 Aug 2026$0.2MSep 2025Ended Oct 2025$8.6M
Wuhan YZY Biopharma Co., Ltd. logo
Wuhan YZY Biopharma Co., Ltd.2496 · HKEX
2 assets: 1 Ph 2, 1 Ph 1M701Phase 1/2 · Non-Small Cell Lung CancerNone on record—$14MDec 2025~4.8 qtrs—
XBiotech logo
XBiotechXBIT · Nasdaq
2 assets: 2 Ph 2NatrunixPhase 2 · Rheumatoid ArthritisPartial signal15 Jan 2027Natrunix · Phase 2—$105MSep 2026~10.3 qtrs$47M
Xbrane Biopharma AB logo
Xbrane Biopharma ABXBRANE · Nasdaq Stockholm
1 asset: 1 Ph 3Ranibizumab (Ximluci)Phase 3 · Age-Related Macular DegenerationNone on record————
Xiamen Amoytop Biotech Co., Ltd. logo
Xiamen Amoytop Biotech Co., Ltd.688278 · SSE
1 asset: 1 Ph 1ACT201Phase 1 · Chronic Hepatitis BFeb 2027ACT201 · Phase 1————
Xuanzhu Biopharmaceutical logo
Xuanzhu Biopharmaceutical2575 · HKEX
4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1BireociclibPhase 3 · HR+/HER2- Metastatic Breast CancerReliable signalNone on record———$26M
Yiling Pharmaceutical Inc. logo
Yiling Pharmaceutical Inc.Private
1 asset: 1 Ph 1FinaminePhase 1 · Parkinson's DiseaseWeak signalNone on record————
Yuhan Corporation logo
Yuhan Corporation000100 · KOSPI
7 assets: 1 approved, 1 Ph 3, 2 Ph 2, 3 otherSarpogrelatePhase 3 · Atherosclerotic Cardiovascular Disease31 Dec 2026Lazertinib · Phase 1—$241MDec 2025——
Zai Lab logo
Zai LabZLAB · Nasdaq
7 assets: 6 approved, 1 Ph 1ZL-1503Phase 1 · Atopic Dermatitis24 Nov 2026Xanomeline/trospium chloride · Phase 3—$560MSep 2026~10.7 qtrs$239M
Zealand Pharma logo
Zealand PharmaZEAL · Nasdaq Copenhagen
6 assets: 2 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1survodutidePhase 3 · ObesityReliable signal8 Dec 2026survodutide · Phase 1—$2.2BMar 2026—~$224M
Z
Zeria Pharmaceutical Co., Ltd.4559 · TSE
1 asset: 1 Ph 3PatiromerPhase 3 · Chronic Kidney DiseasePartial signal1 Dec 2029Patiromer · Phase 2————
Zhejiang Hisun Pharmaceutical logo
Zhejiang Hisun Pharmaceutical600267 · SSE
1 asset: 1 Ph 3HyzetimibePhase 3 · Atherosclerotic Cardiovascular DiseasePartial signalNone on record———$67M
Zhejiang Huahai Pharmaceutical logo
Zhejiang Huahai Pharmaceutical600521 · SSE
1 asset: 1 Ph 2Hypidone (YL-0919)Phase 2 · Major Depressive DisorderPartial signalNone on record———$167M
Zhejiang Jingxin Pharmaceutical Co., Ltd. logo
Zhejiang Jingxin Pharmaceutical Co., Ltd.002020 · SZSE
2 assets: 1 Ph 2, 1 Ph 1JX11502MAPhase 2 · SchizophreniaPartial signalNone on record————
Zydus Lifesciences logo
Zydus LifesciencesZYDUSLIFE · NSE
5 assets: 1 approved, 3 Ph 3, 1 Ph 2DesidustatPhase 3 · Chronic Kidney DiseasePartial signal31 Dec 2026Saroglitazar · Phase 1———$256M
1ST Biotherapeutics, Inc. logo
1ST Biotherapeutics, Inc.Private
2 assets: 2 Ph 1FB-101Phase 1 · Parkinson's DiseaseWeak signalDec 2027FB-101 · Phase 1————
35Pharma logo
35PharmaPrivate
1 asset: 1 Ph 2HS235Phase 1/2 · Heart FailureWeak signalMar 2028HS235 · Phase 1/2————
7 Hills Pharma, LLC logo
7 Hills Pharma, LLCPrivate
1 asset: 1 Ph 2AlintegimodPhase 1/2 · Non-Small Cell Lung Cancer31 Dec 2027Alintegimod · Phase 1/2————
89bio logo
89bioPrivate
1 asset: 1 Ph 3PegozaferminPhase 3 · MASH / NASHPartial signal2 Mar 2027Pegozafermin · Phase 1—$129MJun 2025Ended Oct 2025$421M
A. Menarini logo
A. MenariniPrivate
8 assets: 3 approved, 5 Ph 3MirogabalinPhase 3 · Diabetic Peripheral Neuropathic PainReliable signalNov 2026Obicetrapib · Phase 3————
A
A&G Pharmaceutical Inc.Private
1 asset: 1 Ph 1AG-01Phase 1 · Non-Small Cell Lung CancerNone on record————
A2 Biotherapeutics Inc. logo
A2 Biotherapeutics Inc.Private
4 assets: 4 Ph 2A2B395Phase 1/2 · Non-Small Cell Lung CancerDec 2026A2B530 · Phase 1/2————
Aardvark Therapeutics logo
Aardvark TherapeuticsPrivate
1 asset: 1 Ph 3ARD-101Phase 3 · Prader-Willi SyndromePartial signalNone on record————
A
AbcentraPrivate
1 asset: 1 Ph 2OrticumabPhase 2 · Atherosclerotic Cardiovascular DiseasePartial signal8 Feb 2027Orticumab · Phase 2————
AbelZeta Pharma, Inc. logo
AbelZeta Pharma, Inc.Private
1 asset: 1 Ph 2Trovocabtagene autoleucel (C-CAR088)Phase 1/2 · Multiple MyelomaWeak signalNone on record————
A
ABL BioPrivate
1 asset: 1 Ph 2givastomigPhase 2 · Gastric CancerDec 2026givastomig · Phase 1————
ABLi Therapeutics, Inc. logo
ABLi Therapeutics, Inc.Private
1 asset: 1 Ph 2Risvodetinib (IkT-148009)Phase 2 · Parkinson's DiseaseWeak signalNone on record————
Accord BioPharma Inc. logo
Accord BioPharma Inc.Private
1 asset: 1 approvedApproved assets onlyNone on record————
Accord Healthcare logo
Accord HealthcarePrivate
2 assets: 1 approved, 1 Ph 3SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal30 Dec 2026Serplulimab · Phase 1————
A
Accro Bioscience LimitedPrivate
1 asset: 1 Ph 2AC-201Phase 2 · PsoriasisNone on record————
Accropeutics (Accro Bioscience) logo
Accropeutics (Accro Bioscience)Private
1 asset: 1 Ph 2AC-101Phase 2 · Ulcerative ColitisNone on record————
ACEA Therapeutics logo
ACEA TherapeuticsPrivate
1 asset: 1 Ph 2STI-6129Phase 1/2 · Multiple Myeloma31 Dec 2026STI-6129 · Phase 1/2————
Aché Laboratórios Farmacêuticos S.A. logo
Aché Laboratórios Farmacêuticos S.A.Private
1 asset: 1 otherDihydroergotamine mesylate/Dipyrone/Caffeine (Cefaliv)MigraineNone on record————
Aclipse Therapeutics logo
Aclipse TherapeuticsPrivate
1 asset: 1 Ph 3LobeglitazonePhase 3 · Type 2 DiabetesPartial signalNone on record————
Acrotech Biopharma logo
Acrotech BiopharmaPrivate
3 assets: 3 approvedApproved assets onlyDec 2026difamilast · Phase 3————
Actio Biosciences, Inc. logo
Actio Biosciences, Inc.Private
1 asset: 1 Ph 2ABS-1230Phase 2 · EpilepsyDec 2026ABS-1230 · Phase 1————
Adamas Pharmaceuticals logo
Adamas PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
ADARx Pharmaceuticals logo
ADARx PharmaceuticalsPrivate
1 asset: 1 Ph 1ADX-850Phase 1 · HypertensionNone on record————
Addimmune logo
AddimmunePrivate
1 asset: 1 Ph 1AGT103-TPhase 1 · HIVWeak signalNone on record————
Addpharma logo
AddpharmaPrivate
3 assets: 1 Ph 3, 1 Ph 1, 1 otherAD-209Phase 3 · HypertensionPartial signalNone on record————
Adiso Therapeutics logo
Adiso TherapeuticsPrivate
1 asset: 1 Ph 1PegmispotidePhase 1 · Ulcerative ColitisWeak signalNone on record————
Advanced BioDesign logo
Advanced BioDesignPrivate
1 asset: 1 Ph 2ABD-3001Phase 1/2 · Acute Myeloid LeukemiaNone on record————
ADvantage Therapeutics logo
ADvantage TherapeuticsPrivate
1 asset: 1 Ph 2AD04Phase 2 · Alzheimer's DiseaseDec 2026AD04 · Phase 2————
Advanz Pharma logo
Advanz PharmaPrivate
4 assets: 3 approved, 1 otherAflibercept (Mynzepli)Age-Related Macular DegenerationNone on record————
Advenchen Laboratories logo
Advenchen LaboratoriesPrivate
2 assets: 2 Ph 3ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signalJul 2027Apatinib · Phase 2————
Advesya SAS logo
Advesya SASPrivate
1 asset: 1 Ph 2CCTx-001Phase 1/2 · Acute Myeloid LeukemiaJul 2027CCTx-001 · Phase 1/2————
A
Aeira Pte. Ltd.Private
1 asset: 1 Ph 3stapokibartPhase 3 · Atopic DermatitisReliable signalFeb 2027stapokibart · Phase 3————
Aelix Therapeutics logo
Aelix TherapeuticsPrivate
1 asset: 1 Ph 2HTI vaccine (ChAdOx1.HTI/MVA.HTI)Phase 2 · HIVPartial signalNone on record————
Aeovian Pharmaceuticals, Inc. logo
Aeovian Pharmaceuticals, Inc.Private
1 asset: 1 Ph 2AV078Phase 2 · Epilepsy1 Sep 2027AV078 · Phase 2————
A
AffaMed TherapeuticsPrivate
2 assets: 1 approved, 1 Ph 3fasedienolPhase 3 · Social Anxiety DisorderPartial signalNone on record————
Affini-T Therapeutics, Inc. logo
Affini-T Therapeutics, Inc.Private
1 asset: 1 Ph 2AFNT-211Phase 1/2 · Non-Small Cell Lung CancerNone on record————
AgeneBio logo
AgeneBioPrivate
1 asset: 1 Ph 3AGB101Phase 2/3 · Alzheimer's DiseasePartial signalNone on record————
Agepha Pharma logo
Agepha PharmaPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Agyany Pharma Ltd logo
Agyany Pharma LtdPrivate
1 asset: 1 Ph 3AmbroxolPhase 3 · Parkinson's DiseasePartial signalNone on record————
A
AiBtl BioPharmaPrivate
1 asset: 1 Ph 2PDC-1421Phase 2 · Major Depressive DisorderPartial signal28 Feb 2028PDC-1421 · Phase 1/2————
A
AirNexis TherapeuticsPrivate
1 asset: 1 Ph 3HSK39004Phase 3 · Chronic Obstructive Pulmonary Disease11 Jun 2027HSK39004 · Phase 3————
AJU Pharm logo
AJU PharmPrivate
2 assets: 2 Ph 3Valsartan/amlodipine/chlorthalidone (AJU-C52)Phase 3 · HypertensionReliable signalNone on record————
Akros Pharma logo
Akros PharmaPrivate
1 asset: 1 Ph 2JTT-861Phase 2 · Heart FailurePartial signalNone on record————
Alentis Therapeutics AG logo
Alentis Therapeutics AGPrivate
2 assets: 2 Ph 2ALE.P02Phase 1/2 · Non-Small Cell Lung Cancer15 Feb 2028ALE.P02 · Phase 1/2————
Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca) logo
Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca)Private
3 assets: 2 approved, 1 Ph 2ALXN1820Phase 2 · ANCA-Associated Vasculitis7 Dec 2026Eculizumab · Phase 3————
Alfasigma logo
AlfasigmaPrivate
2 assets: 1 approved, 1 Ph 3filgotinibPhase 3 · Rheumatoid ArthritisReliable signal20 Apr 2027Rifaximin (Xifaxan) · Approved————
A
Alfresa PharmaPrivate
1 asset: 1 approvedApproved assets onlyApr 2027Epinephrine · Approved————
Allife Medical Science and Technology logo
Allife Medical Science and TechnologyPrivate
2 assets: 2 Ph 1ALF202Phase 1 · Atherosclerotic Cardiovascular DiseaseWeak signalNone on record————
A
Alligator BiosciencePrivate
1 asset: 1 Ph 2ALG.APV-527Phase 1/2 · Solid TumorsNone on record————
Allodynic Therapeutics, LLC logo
Allodynic Therapeutics, LLCPrivate
1 asset: 1 Ph 3Naltrexone/Acetaminophen (ALLOD-2)Phase 2/3 · MigraineNone on record————
A
Allorion TherapeuticsPrivate
1 asset: 1 Ph 2AVZO-021Phase 1/2 · HR+/HER2- Metastatic Breast Cancer31 Jan 2028AVZO-021 · Phase 1/2————
AllRock Bio logo
AllRock BioPrivate
1 asset: 1 Ph 2ROC-101Phase 2 · Pulmonary Arterial HypertensionMar 2027ROC-101 · Phase 2————
Allyx Therapeutics logo
Allyx TherapeuticsPrivate
1 asset: 1 Ph 1BMS-984923Phase 1 · Alzheimer's DiseaseWeak signalNone on record————
A
Almac DiscoveryPrivate
1 asset: 1 Ph 2ZedoresertibPhase 1/2 · HR+/HER2- Metastatic Breast CancerDec 2027Zedoresertib · Phase 1————
Alpha Biopharma (Jiangsu) Co., Ltd. logo
Alpha Biopharma (Jiangsu) Co., Ltd.Private
1 asset: 1 Ph 3ZorifertinibPhase 2/3 · Non-Small Cell Lung CancerPartial signal23 Apr 2028Zorifertinib · Phase 1————
Alphyn Biologics logo
Alphyn BiologicsPrivate
1 asset: 1 Ph 2zabalafinPhase 2 · Atopic DermatitisNone on record————
Alterome Therapeutics, Inc. logo
Alterome Therapeutics, Inc.Private
1 asset: 1 Ph 1ALTA3263Phase 1 · Non-Small Cell Lung CancerMay 2029ALTA3263 · Phase 1————
AltruBio logo
AltruBioPrivate
1 asset: 1 Ph 2ALTB-268Phase 2 · Ulcerative ColitisWeak signalNone on record————
Amandala Neuro Limited logo
Amandala Neuro LimitedPrivate
1 asset: 1 Ph 2ELE-101Phase 1/2 · Major Depressive DisorderNone on record————
Amicus Therapeutics logo
Amicus TherapeuticsPrivate
1 asset: 1 approvedApproved assets only31 Dec 2026Migalastat · Phase 3————
Amorepacific logo
AmorepacificPrivate
1 asset: 1 Ph 3asivatrepPhase 3 · Atopic DermatitisReliable signalNone on record————
Amphista Therapeutics Ltd logo
Amphista Therapeutics LtdPrivate
1 asset: 1 Ph 1AMX-883Phase 1 · Acute Myeloid Leukemia4 Dec 2028AMX-883 · Phase 1————
AmyriAD Therapeutics B.V. logo
AmyriAD Therapeutics B.V.Private
1 asset: 1 Ph 2Inidascamine (RL-007)Phase 2 · Cognitive Impairment Associated with SchizophreniaNone on record————

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415